Replies to post #34129 on Ayala Pharmaceuticals Inc (ADXS)

[ignatiusrielly35]

Impeccably stated, Hovacre.

[DewDiligence]

Re: NEO delay

…news that has come from Advaxis in 2017…initiation of the NEO study.

Unfortunately, ADXS’ guidance for when the first NEO patient will be dosed has been pushed back to IH18,* according to the 9/11/17 PR.

Thus, 12-15 months will elapse from the time ADXS got FDA approval of the NEO IND in Mar 2017 (#msg-129238272) until the first patient in the phase-1 trial is dosed. Such a long delay can only mean one thing: ADXS does not yet have the NEO manufacturing squared away.

This is a pretty big setback and is probably the main impetus for the sharp decline in the share price since the 9/11/17 PR, IMO.

*In practice, “1H18” almost always means 2Q18; else the guidance would be given as “1Q18.”